α-synuclein (SNCA)
Synuclein alpha, encoded by the SNCA gene, is a small presynaptic protein best known for its central role in the biology and pathology of Parkinson's disease and related synucleinopathies.
Synuclein alpha, encoded by the SNCA gene, is a small presynaptic protein best known for its central role in the biology and pathology of Parkinson's disease and related synucleinopathies. Under normal conditions, α-synuclein is associated with neuronal membranes and synaptic function, but when it misfolds or accumulates abnormally it can form oligomers and aggregates that are strongly linked to neurodegeneration. Its pathological aggregation is a defining feature of Parkinson's disease and is also implicated in multiple system atrophy and other disorders characterized by α-synuclein deposition.
Biomedically, α-synuclein is important both as a disease biomarker and as a therapeutic target. Recent research has focused on how oxidative stress, mitochondrial dysfunction, inflammation, ferroptosis, and impaired protein clearance contribute to α-synuclein aggregation and toxicity. These studies have also explored strategies to reduce aggregated α-synuclein, block its membrane interactions, enhance its degradation through the autophagy-lysosomal pathway, or neutralize downstream injury in dopaminergic neurons.
Where the papers sit
13 papers from the last 6 months study α-synuclein (SNCA) directly · updated from PubMed 4 Oct 2026
Study type 1 clinical trial · 1 observational · 8 preclinical · 3 unclassified
Themes one subject · 1 paradigm shift
Those 13 are all about one subject.
-
Parkinson’s Disease Mechanisms and Therapies
α-Synuclein aggregation, mitochondrial dysfunction, oxidative stress and NLRP3-driven inflammation recur as linked mechanisms of Parkinson’s disease progression. Therapeutic work is moving toward combined strategies, including SS-31, anti-α-synuclein antibody amlenetug, targeted DNA nanocarriers and zinc-tannic acid nanoparticles. Some interventions show promise, but chlorogenic acid failed to provide neuroprotection in a chronic model. Multi-omics, biomarkers and cognitive trajectories are being used to improve staging and identify patients most likely to benefit.
Mitochondria emerge as active determinants of α-synuclein handling, not merely victims of its toxicity
The SH-SY5Y cell model exposed to α-synuclein fibrils and the cellular aggregation-prone-protein model examined by genome-wide CRISPR screening both depart from the assumption that mitochondrial involvement is chiefly a downstream consequence of α-synuclein damage. Fibrils induced mitochondrial cristae defects and increased mitochondrial-derived-vesicle budding, while mitochondrial localization retained α-synuclein in a compartment that hindered degradation; inhibiting eIF5A displaced α-synuclein from mitochondria and enhanced its proteasomal clearance. Together, these findings make mitochondria active regulators of α-synuclein trafficking, vesicle production, and degradation, shifting the therapeutic problem from simply protecting mitochondria from α-synuclein toxicity to altering the mitochondrial compartment's handling of the protein 42258734Jun 42098118May.
Papers
The 13 papers from the last 6 months that study α-synuclein (SNCA) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.
By theme
Parkinson’s Disease Mechanisms and Therapies (13)
- α1-Antitrypsin attenuates microglial NLR family pyrin domain containing 3 inflammasome activation via cannabinoid receptor 2 signaling to ameliorate α-synucleinopathy-related behavioral deficits. Molecular biomedicine · 20 Sept 2026 PMID 42763829
- Chlorogenic Acid Fails to Confer Neuroprotection in a Chronic Mouse Model of Parkinson's Disease. Molecular neurobiology · 27 Aug 2026 PMID 42661104
- A Brain-Targeted DNA Delivery Nanocarrier Modulator for Synergistic Therapy of Parkinson's Disease. ACS applied materials & interfaces · 2 Jul 2026 PMID 42390437
- Neuropsychological Profile and Cognitive Trajectories of Patients With Biomarker Evidence of Alzheimer Disease or Dementia With Lewy bodies. Neurology · 1 Jul 2026 PMID 42385111
- Interplay of Genetic and Biomarker Signatures in Oxidative Stress and Inflammation: Advancing Parkinson's Disease Research Through Emerging Omics Technologies. Current neurovascular research · 9 Jun 2026 PMID 42261156
- Alpha-synuclein fibrils induce budding of mitochondrial-derived vesicles. Proceedings of the National Academy of Sciences of the United States of America · 8 Jun 2026 PMID 42258734
- Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function. Chemical biology & drug design · 1 Jun 2026 PMID 42219795
- Molecular Insights into Parkinson's Disease Progression: A Multi-omics Analysis of the Substantia Nigra Pars Compacta across Braak Stages. Experimental neurobiology · 14 May 2026 PMID 42130054
- Mitochondria serve as a holdout compartment for aggregation-prone proteins hindering efficient degradation. Nature communications · 7 May 2026 PMID 42098118
- Multi-omics analysis of deep brain stimulation associated with brain-gut axis modulation and symptom amelioration in a Parkinson's disease mouse model. Biology direct · 7 May 2026 PMID 42092952
- Beyond Amyloids: Neuroprotective Potential of Betanin and its Derivatives Against Alpha-Synuclein Aggregates and ROS Overload in Parkinson's Disease. Journal of molecular neuroscience : MN · 4 May 2026 PMID 42081152
- Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial. The Lancet. Neurology · 27 Apr 2026 PMID 42044642
- Multifunctional Zinc-Tannic Acid Nanoparticles Target α-Synuclein Aggregation and Oxidative Stress in Parkinson's Disease. Nano letters · 18 Apr 2026 PMID 41999339
By study type
Clinical trials (1)
- Safety and efficacy of the anti-α-synuclein monoclonal antibody amlenetug for the treatment of patients with multiple system atrophy (AMULET): a phase 2, randomised, double-blind, multicentre trial. The Lancet. Neurology · 27 Apr 2026 PMID 42044642
Observational studies and case reports (1)
- Neuropsychological Profile and Cognitive Trajectories of Patients With Biomarker Evidence of Alzheimer Disease or Dementia With Lewy bodies. Neurology · 1 Jul 2026 PMID 42385111
Preclinical: animal, cell and lab studies (8)
- α1-Antitrypsin attenuates microglial NLR family pyrin domain containing 3 inflammasome activation via cannabinoid receptor 2 signaling to ameliorate α-synucleinopathy-related behavioral deficits. Molecular biomedicine · 20 Sept 2026 PMID 42763829
- Chlorogenic Acid Fails to Confer Neuroprotection in a Chronic Mouse Model of Parkinson's Disease. Molecular neurobiology · 27 Aug 2026 PMID 42661104
- A Brain-Targeted DNA Delivery Nanocarrier Modulator for Synergistic Therapy of Parkinson's Disease. ACS applied materials & interfaces · 2 Jul 2026 PMID 42390437
- Alpha-synuclein fibrils induce budding of mitochondrial-derived vesicles. Proceedings of the National Academy of Sciences of the United States of America · 8 Jun 2026 PMID 42258734
- Therapeutic Peptide SS-31 Modulates Membrane Binding and Aggregation of α-Synuclein and Restores Impaired Mitochondrial Function. Chemical biology & drug design · 1 Jun 2026 PMID 42219795
- Mitochondria serve as a holdout compartment for aggregation-prone proteins hindering efficient degradation. Nature communications · 7 May 2026 PMID 42098118
- Beyond Amyloids: Neuroprotective Potential of Betanin and its Derivatives Against Alpha-Synuclein Aggregates and ROS Overload in Parkinson's Disease. Journal of molecular neuroscience : MN · 4 May 2026 PMID 42081152
- Multifunctional Zinc-Tannic Acid Nanoparticles Target α-Synuclein Aggregation and Oxidative Stress in Parkinson's Disease. Nano letters · 18 Apr 2026 PMID 41999339
Unclassified: not yet indexed with MeSH (3)
- Interplay of Genetic and Biomarker Signatures in Oxidative Stress and Inflammation: Advancing Parkinson's Disease Research Through Emerging Omics Technologies. Current neurovascular research · 9 Jun 2026 PMID 42261156
- Molecular Insights into Parkinson's Disease Progression: A Multi-omics Analysis of the Substantia Nigra Pars Compacta across Braak Stages. Experimental neurobiology · 14 May 2026 PMID 42130054
- Multi-omics analysis of deep brain stimulation associated with brain-gut axis modulation and symptom amelioration in a Parkinson's disease mouse model. Biology direct · 7 May 2026 PMID 42092952
Written from 13 PubMed abstracts, each one listed by PMID above. Published: 2026-06-15. Last written: 2026-09-22 by GPT. Drafted by language models from published abstracts; not medical advice.